Back to Feed
Blood|Peer-Reviewed

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma

Mark R. Dowling, Edward R. Scheffer Cliff, Anthony Jeffrey, Catelyn Cashion, Stephen Boyle, Jian Li, Thomas Buss, Ross MacDonald, Anastasia Edelkina, Hamish W. Scott, Nicole L. O’Leary, Michelle W. Keir, Safia Belbachir, David A. Westerman, Constantine S. Tam, P. Joy Ho, Simon J. Harrison, Allison Barraclough, Shafqat Inam, Emily Blyth, Andrea S. Henden, Vinay Vanguru, Michael J. Dickinson

Abstract

Abstract In this retrospective analysis of 584 patients who received chimeric antigen receptor T-cell therapy for large B-cell lymphoma at 6 Australian centers, no association was found between time of infusion and outcome, accounting for confounders, suggesting minimal clinical impact of chronobiology in this setting.

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma | StemCell Pulse | StemCell Pulse